• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

    5/7/25 4:13:48 PM ET
    $TLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLX alert in real time by email

    MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging safety profile and efficacy in aggressive, radioiodine-resistant (RAI-R) thyroid cancer1.

    TLX400 (177Lu-DOTAGA.Glu.(FAPi)2) has been in-licensed by Telix as part of a portfolio of next-generation therapeutic and diagnostic ("theranostic") radiopharmaceutical candidates2. TLX400 has potential clinical utility in several oncology indications. The publication provides further validation of the safety profile and potential efficacy of Telix's lead FAP therapeutic candidate.

    In this peer-reviewed manuscript, Dr. Sanjana Ballal and colleagues report results from 73 heavily pre-treated patients with RAI-R follicular thyroid carcinoma3. The authors conclude that TLX400 therapy demonstrated a promising safety profile and efficacy in aggressive, RAI-R thyroid cancer, achieving a median progression-free survival (PFS) and overall survival (OS) of 29 and 32 months, respectively, with a manageable adverse event profile.

    The therapeutic approach to radioiodine-refractory thyroid cancer has advanced with tyrosine kinase inhibitors (TKIs) such as sorafenib and lenvatinib, supported by the DECISION trial4 and SELECT study5 results. However, their potential risks, including significant side effects, require careful management, particularly in patients with comorbidities such as cardiac issues, hypertension, stroke, and kidney dysfunction, who may not be optimal candidates for TKI therapy. Lutetium-177 (177Lu)-FAP inhibitor therapy marks a significant advancement in thyroid cancer theranostics, where FAP in cancer-associated fibroblasts (CAFs) influences the tumor microenvironment (TME), angiogenesis, and chemotherapy resistance. CAFs interact with cancer cells, fostering tumor growth and aggressiveness, highlighting their significance as therapeutic targets and in elucidating tumor progression mechanisms.

    Dr. Sanjana Ballal, Senior Researcher at the All India Institute of Medical Sciences (AIIMS, New Delhi), investigator and lead author, commented, "This preliminary study highlights the promising safety profile and efficacy of TLX400 therapy in aggressive radioiodine-resistant thyroid cancer, including refractory cases. Notably, in the cohort of patients with reported efficacy, the treatment demonstrated median OS and PFS durations of 32 and 29 months, with a promising 50% partial response rate. Adverse events, primarily hematotoxicity – typical of radiopharmaceuticals – were manageable, emphasizing potential as a promising treatment option for this challenging patient population."

    TLX400 is differentiated by a novel structure that drives prolonged tumor retention while minimizing off-target uptake, designed to overcome the limitations seen with first-generation FAP-targeting compounds. These candidates have extensive pre-clinical and clinical data covering a range of tumors6. Telix is exploring the clinical utility of the FAP portfolio across a range of solid tumors, including bladder cancer.

    Dr. David N. Cade, Group Chief Medical Officer, Telix, added, "We are highly encouraged by these data for TLX400, which compare favourably to TKIs – the standard of care treatment in patients with thyroid cancer – for OS and PFS. This provides further validation of the safety profile and efficacy potential enabled by the novel design of these FAP-targeting therapeutic candidates."

    The Thyroid publication is available online at: https://www.liebertpub.com/doi/10.1089/thy.2024.0229

    About Telix Pharmaceuticals Limited

    Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ:TLX).

    Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

    TLX400 has not received a marketing authorization in any jurisdiction.

    Telix Investor Relations

    Ms. Kyahn Williamson

    Telix Pharmaceuticals Limited

    SVP Investor Relations and Corporate Communications

    Email: [email protected]

    Legal Notices

    You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

    The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

    This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

    ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

    ________________________

    1 Ballal et al. Thyroid. 2025. https://www.liebertpub.com/doi/10.1089/thy.2024.0229

    2 Telix ASX disclosure 12 March 2025.

    3 The data were collected as part of a compassionate use program covered by an overarching protocol, approved by the institutional ethics board.

    4 Brose et al. Lancet. 2014.

    5 Schlumberger et al. N Engl J Med. 2015.

    6 See Telix investor presentation lodged with the ASX on 19 November 2024.



    Primary Logo

    Get the next $TLX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TLX

    DatePrice TargetRatingAnalyst
    7/3/2025$23.00Buy
    H.C. Wainwright
    6/5/2025$22.00Outperform
    Wedbush
    11/15/2024$21.00Buy
    UBS
    More analyst ratings

    $TLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT

      MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for

      6/23/25 7:15:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Precision Medicine Announces AlFluor Radiochemistry Platform

      MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluor™. The AlFluor™ platform technology enables flexible radiolabeling of PSMA2 with either AlF or gallium-68 (68Ga). It also has the potential to be used with ligands targeting NETs3 and FAP4, as well as other novel imaging agents under development by Telix and its strategic partners. Developed to combine the imaging benefits of 18F with the convenience of 68Ga kit-based workflows, the AlFluor™ platform supports both centr

      6/20/25 8:00:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

      MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix", "the Company") today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24. Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix's TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix

      6/19/25 8:18:38 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLX
    SEC Filings

    See more
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      6/11/25 5:09:40 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      5/21/25 8:39:11 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Telix Pharmaceuticals Limited

      6-K - Telix Pharmaceuticals Ltd (0002007191) (Filer)

      4/28/25 6:37:46 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Telix Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $23.00

      7/3/25 7:52:31 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Telix Pharmaceuticals with a new price target

      Wedbush initiated coverage of Telix Pharmaceuticals with a rating of Outperform and set a new price target of $22.00

      6/5/25 7:35:43 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Telix Pharmaceuticals with a new price target

      UBS initiated coverage of Telix Pharmaceuticals with a rating of Buy and set a new price target of $21.00

      11/15/24 8:23:07 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLX
    Financials

    Live finance-specific insights

    See more
    • Telix Reports US$186M Q1 Revenue, Up 62% YOY

      MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-over-quarter increase of 31% (Q4 2024: $142 million) and includes: $151 million from global sales of Illuccix®, up 35% over the prior year corresponding quarter (Q1 2024: $112 million

      4/22/25 4:17:09 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Telix Completes Acquisition of RLS (USA) Inc.

      MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals. The acquisition immediately enhances Telix's presence in the United States (U.S.), with a network of over 30 radiopharmacies3 dispensing radiopharmaceuticals manufactured by Telix and other companies, while bringing a team of highly-skilled and multi-disciplinary radiopharmaceutical professionals into the Company. Th

      1/27/25 4:43:43 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Telix Appoints Paul Schaffer as Chief Technology Officer

      MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada's particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotr

      4/7/25 6:30:00 AM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anne Whitaker Appointed as Non-Executive Director

      MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

      4/3/25 6:13:56 PM ET
      $ICLR
      $TLX
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

      MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities1. This transaction delivers a pipeline of drug candidates against validated cancer targets including DLL32 and integrin αvβ63, as well as a panel of other agents against novel targets in early discovery stage.

      1/30/25 4:57:53 PM ET
      $TLX
      Biotechnology: Pharmaceutical Preparations
      Health Care